{
    "2018-11-19": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Sandoz and Pear Therapeutics announce launch of reSETÂ® for treatment of patients with Substance Use Disorder",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "Pear Therapeutics",
                        "reSET",
                        "Substance Use Disorder"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Sandoz, Pear Launch ReSET For Treatment Of Patients With Substance Use Disorder",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "Pear",
                        "ReSET",
                        "Substance Use Disorder"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "Promacta",
                        "label expansion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs",
                "features": {
                    "keywords": [
                        "drug pricing",
                        "Pfizer",
                        "cost increase"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Health Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more",
                "features": {
                    "keywords": [
                        "Chelsea Clinton",
                        "Verily",
                        "smart lens",
                        "diabetes",
                        "East Bay biotech"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis Is Set For 'Higher Returns And Growth,' Goldman Sachs Says In Upgrade",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Goldman Sachs",
                        "upgrade",
                        "returns",
                        "growth"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}